Retiree paints birdhouses for cancer patients
MOUNT LAUREL, N.J. (AP) — Bob Taylor sits at his kitchen table with the sunlight shining in through a big window. He dips his small paint brush into the bright pink paint, and strokes the wooden...
VA considering additions for illnesses caused by Agent Orange exposure
Although it’s taken more than one year of review, the U.S. Department of Veterans Affairs is considering adding six new suspected diseases to its list of illnesses that are caused by exposure to Agent Orange.
The new diseases include bladder cancer, Parkinsonism (Parkinson-like symptoms), hypothyroidism, stroke and hypertension.
The possible additions were announced in November by U.S. Secretary of Veterans Affairs David J. Shulkin.
TRENTON, N.J. (AP) — U.S. regulators have approved a new drug that harnesses the immune system to treat bladder cancer that has spread after chemotherapy or surgery.
The Food and Drug Administration on Monday approved Imfinzi for advanced bladder cancer, along with a companion diagnostic test for identifying which patients are most likely to benefit from it.
Monument Marathon helps cancer survivor continue down the path of health
Lisa Stinson has found a new way of living after a health scare almost one year ago. Stinson was diagnosed with stage IV bladder cancer, also referred to as metastatic bladder cancer, in October 2015. After chemotherapy and a few surgeries, her cancer went into remission in March of this year.
Stinson is a licensed clinical psychologist with an office in North Platte.
- Business WireBladder Cancer Clinical Trial Pipeline Highlights 2019 - Global Forecast to 2024 - ResearchAndMarkets.comJune 5, 2019
- Business WireThe Urothelial Cancer Drugs Market: Worldwide Growth, Trends and Forecasts (2019-2024) - ResearchAndMarkets.comJune 4, 2019
- Business WireRainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)June 3, 2019
- Business WireSesen Bio Announces Acceptance of Analytical Comparability Plan by the U.S. Food and Drug Administration to Support the BLA and Commercialization of Its Lead Asset, Vicinium® for Non-Muscle Invasive Bladder CancerMay 21, 2019
- Business WireRainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell ActivationMay 20, 2019